๐
Nuedexta
dextromethorphan hydrobromide;quinidine sulfate
Neurobehavioral Manifestations
๐ซ Withdrawn
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Nuedexta is indicated for the symptomatic treatment of pseudobulbar affect (PBA) in adults. Efficacy has only been studied in patients with underlying amyotrophic lateral sclerosis or multiple sclerosis.
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/nuedexta